Skip to content
View in the app

A better way to browse. Learn more.

Thailand News and Discussion Forum | ASEANNOW

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Joining Trans-Pacific group 'will have no impact on Compulsory Licensing of drugs'

Featured Replies

Joining Trans-Pacific group 'will have no impact on Compulsory Licensing of drugs'

By THE NATION

 

800_640775a3f5eb6f9.jpg?v=1592636162

 

The Department of Intellectual Property has eased public concerns about Thailand losing the the right to Compulsory Licensing (CL) of drugs if it joins the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).

 

“The CPTPP does not prohibit the use of drug CL or has any regulations that will force Thailand to extend the protection period of drug CL or allow the monopoly of drug tests,” the department said.

 

The drug CL under CPTPP will comply with the regulations of World Trade Organization (WTO) that focuses on the use for non-commercial purposes or to remedy emergency situations such as the Covid-19 outbreak, the department added.

 

“The Thai government will still be able to manufacture, sell or import drugs at a lower price from other sellers during emergency situations despite the drugs being protected under CL,” it added.

 

The CPTPP also allows member countries to use their own discretion in considering which situations are emergency as different countries have different priorities in handling problems.

 

“As for the forced extension of drug CL and monopoly of drug tests, these two issues are not under the scope of the CPTPP although they had been introduced by the United States when forming the Trans-Pacific Partnership, the former version of CPTPP,” said the department.

 

“When the US left the partnership in 2017, the remaining 11 members decided to revoke the two issues, therefore Thailand will not be forced to extend drug CL or allow the monopoly of drug tests under CPTPP.

 

“It is unlikely that the two issues will be reintroduced in the future, as it will require unanimous agreement from all member countries, and Thailand will have the right to veto the issue if we join the group,” the department said.

 

Source: https://www.nationthailand.com/news/30389980

 

nation.jpg

-- © Copyright The Nation Thailand 2020-06-22
 

"Thailand will have the right to veto the issue if we join the group,”

Could well be a part of the agreement, should Thailand wish to join the Trans Pacific Partnership Agreement, that this right to veto issues about drug production and sales, as they would still want to retain their monopoly. 

The TPPA is about trade, not monopolies.

 

6 hours ago, webfact said:

The CPTPP also allows member countries to use their own discretion in considering which situations are emergency as different countries have different priorities in handling problems.

Thailands loop-hole.

what about day to day drugs?  The Thai generic copies are much cheaper

1 hour ago, Toany said:

what about day to day drugs?  The Thai generic copies are much cheaper

 

1 hour ago, Toany said:

what about day to day drugs?  The Thai generic copies are much cheaper

That is a very good question. Most drugs you buy here in a pharmacy are a lot cheaper than in Western Countries. 

 

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.